Adelante

Adelante Therapeutics is a biotechnology company focused on the development of next-generation targeted protein degradation (TPD) therapies. Founded by Dr. Craig Crews, a pioneer in the field of PROTACs, the company leverages advanced chemical biology to design small molecules that harness the body's natural protein disposal systems. Their platform aims to address previously undruggable targets in oncology and inflammatory diseases by inducing the degradation of disease-causing proteins. Adelante is currently in the pre-clinical stage, optimizing its lead candidates and expanding its pipeline of molecular glues and bifunctional degraders.